Latest News and Press Releases
Want to stay updated on the latest news?
-
NEEDHAM, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
-
Dr. Scott E. Eggener to present safety data from phase 2 clinical trial of CAN-2409 in patients with localized, low to intermediate risk prostate cancer undergoing active surveillance at AdMeTech...
-
NEEDHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral...
-
NEEDHAM, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral...
-
NEEDHAM, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
-
NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
-
Proceeds to Accelerate Enrollment of Phase 3 Localized Prostate Cancer Clinical Trial and to Advance Late Stage High-Grade Glioma Clinical Program Candel to Expand Clinical Trials in Other...
-
AUBURNDALE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Advantagene, Inc. today announced that the company entered into a clinical trial collaboration with Bristol-Myers Squibb (NYSE:BMY) to evaluate...